Bagcioglu Erman, Solmaz Volkan, Erbas Oytun, Özkul Bahattin, Çakar Burak, Uyanikgil Yigit, Söğüt İbrahim
Department of Clinical Psychology, Ruhr University, Bochum, Germany.
Department of Neurophysiology, Cologne University, Cologne, Germany.
J Neuroimmune Pharmacol. 2023 Jun;18(1-2):9-23. doi: 10.1007/s11481-023-10061-2. Epub 2023 Apr 12.
To evaluate the ameliorating effect of Modafinil on neuroinflammation, behavioral, and histopathological alterations in rats induced by propionic acid (PPA). Thirty male Wistar rats were used in the study, divided into 3 groups of ten subjects. One group served as a control, the subjects in the other two were given 250 mg/kg/day of PPA by intraperitoneal injection over the course of 5 days to induce autism. The experimental design was as follows: Group 1: Normal control (orally-fed control, n = 10); Group 2 (PPA + saline, n = 10): PPA and 1 ml/kg/day % 0.9 NaCl saline via oral gavage; Group 3 (PPA + Modafinil, n = 10) PPA and 30 mg/kg/day Modafinil (Modiodal tablets 100 mg, Cephalon) via oral gavage. All of the groups were investigated for behavioral, biochemical, and histological abnormality. Autism-like behaviors were reduced significantly in the rats treated with PPA. TNF-α, Nerve Growth Factor (NGF), IL-17, IL-2, and NF-KB levels as well as MDA levels and lactate were significantly higher in those treated with PPA compared to the control group. Using immunohistochemical methods, the number of neurons and GFAP immunoreactivity was significantly altered in PPA-treated rats compared to the control. Using Magnetic Resonance Spectroscopy (MRS), we found that lactate levels were significantly higher in the PPA-treated rats, while creatinine levels were significantly decreased. In the rats administered with Modafinil, behavior, neuroinflammation, and histopathological changes brought about by PPA were significantly reversed. Our results demonstrate the potential role of Modafinil in ameliorating PPA-induced neuroinflammation in rats.
为评估莫达非尼对丙酸(PPA)诱导的大鼠神经炎症、行为及组织病理学改变的改善作用。本研究选用30只雄性Wistar大鼠,分为3组,每组10只。一组作为对照组,另外两组的大鼠在5天内每天腹腔注射250mg/kg的PPA以诱导自闭症。实验设计如下:第1组:正常对照组(经口喂养对照组,n = 10);第2组(PPA + 生理盐水,n = 10):PPA和1ml/kg/天的0.9% NaCl生理盐水,经口灌胃;第3组(PPA + 莫达非尼,n = 10):PPA和30mg/kg/天的莫达非尼(100mg莫达非尼片,Cephalon公司),经口灌胃。对所有组进行行为、生化和组织学异常检查。PPA处理的大鼠自闭症样行为显著减少。与对照组相比,PPA处理组的肿瘤坏死因子-α(TNF-α)、神经生长因子(NGF)、白细胞介素-17(IL-17)、白细胞介素-2(IL-2)、核因子-κB(NF-κB)水平以及丙二醛(MDA)水平和乳酸水平显著升高。采用免疫组化方法,与对照组相比,PPA处理的大鼠神经元数量和胶质纤维酸性蛋白(GFAP)免疫反应性显著改变。使用磁共振波谱(MRS),我们发现PPA处理的大鼠乳酸水平显著升高,而肌酐水平显著降低。在给予莫达非尼的大鼠中,PPA引起的行为、神经炎症和组织病理学变化得到显著逆转。我们的结果证明了莫达非尼在改善PPA诱导的大鼠神经炎症中的潜在作用。